Main image Main image

Cend Therapeutics in the News

October 9, 2017

DrugCendR Inc. will participate in the BIO Investor Forum in a session on Wednesday, October 18th, 2017 at 10:30 am PST. The conference takes place on October 17th and 18th Westin St. Francis Hotel, San Francisco. More information on the event website

August 24, 2017




July 30, 2017

Dr. Harri Jarvelainen has joined DrugCendR Inc. as the Chief Operating Officer (COO). He has more than 15 years of scientific, managerial and executive experience in biopharma industry –  bringing small molecule drugs and biologicals from discovery to early development in multiple therapeutic areas. He has contributed to more than 30 first-in-man projects and has collaborated with and consulted for more than 50 biotechnology companies over the years. Erkki Ruoslahti, CEO of DrugCendR, stated: “We are pleased to have Dr. Jarvelainen in our team. He has provided a valuable service to our company in his previous role as a consultant role and will now be instrumental in the developing DrugCendR from a start-up into a biotech ready for the clinic. DrugCendR is currently completing the final preclinical, CMC and regulatory activities for its lead compound CEND-1 in preparation for a Phase I/IIa clinical study program. The trial is expected to initiate in early 2018.